Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated Diverticulitis: a Prospective Multicenter Randomized Trial

Status: Recruiting
Location: See all (20) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed to be a multicentre, prospective, comparative, randomised trial, evaluating the efficacy of two surgical strategies for the treatment of generalised peritonitis due to perforated diverticulitis. Results will be analysed according to an intention to treat principle (after selection and patient consent). Immediately before surgery, the patient will be randomly assigned to sigmoidectomy with primary anastomosis or to sigmoidectomy with primary anastomosis and diverting stoma. Sigmoidectomy will be performed through a midline laparotomy or laparoscopically according to the standard technique. In the control arm, a protective stoma will be performed at the end of surgery. A stoma reversal operation will be performed at least 3 months after the first operation and after performing a cologram by water soluble contrast between 4 and 8 weeks to check for the absence of fistula or stenosis at the level of the anastomosis. Stoma reversal will be performed with a trephine incision. Post-stoma closure follow-ups will be planned and all morbidity/mortality will be recorded. All patients will be examined at 6, 12, and 24 weeks after the initial surgery, in the surgical department where they were operated; a final study visit will be carried out 12 months (evaluation of primary endpoint) after surgery. The parameters explored at medical examinations will be: • Occurrence of complications • Quality of life assessment

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Patients operated for purulent or fecal peritonitis (Hinchey grade III and IV) secondary to perforated diverticulitis of the left colon and treated by resection with primary anastomosis

• Person informed and having signed his consent. If the patient is unable to sign his consent, the consent will be signed by his representative ((1) the trusted person, or failing that, (2) a family member, or (3) a relative of the person concerned) (Article L1122-1-1 of the CSP). In this case, consent to continue the study will subsequently be requested from the patient. --\> In addition, due to the vital urgency represented by hospitalisation in intensive care for purulent or fecal peritonitis, inclusion without prior collection of the consent of the patient or his/her representative is possible in the case where the patient is not capable of giving consent and his/her representative is not present at the time of inclusion (Article L1122-1-3 of the CSP). In this case, the patient or his/her representative will be informed as soon as possible and his/her written consent will be requested for the possible continuation of this research and the use of the data concerning him/her.

• Patient able to comply with the study protocol, in the investigator's judgment

• Patient affiliated with, or beneficiary of a social security (health insurance) category

Locations
Other Locations
France
CHU Amiens
RECRUITING
Amiens
CH Beauvais
NOT_YET_RECRUITING
Beauvais
CHR Beauvais
NOT_YET_RECRUITING
Beauvais
CHU Besançon
NOT_YET_RECRUITING
Besançon
APHP Avicenne
NOT_YET_RECRUITING
Bobigny
CHU Brest
RECRUITING
Brest
CHU Caen
NOT_YET_RECRUITING
Caen
CHU Clermont Ferrand
NOT_YET_RECRUITING
Clermont-ferrand
APHP Henri Mondor
NOT_YET_RECRUITING
Créteil
CHU Grenoble
NOT_YET_RECRUITING
Grenoble
CHU Limoges
NOT_YET_RECRUITING
Limoges
CHU Lyon
NOT_YET_RECRUITING
Lyon
APHM Hôpital Nord
RECRUITING
Marseille
APHM La Timone
RECRUITING
Marseille
CHU Nancy
NOT_YET_RECRUITING
Nancy
CHU Nantes
NOT_YET_RECRUITING
Nantes
CHU Nimes
NOT_YET_RECRUITING
Nîmes
APHP St Antoine
NOT_YET_RECRUITING
Paris
CHU Rouen
RECRUITING
Rouen
CHU Tours
RECRUITING
Tours
Contact Information
Primary
Valérie BRIDOUX, Pr
valerie.bridoux@chu-rouen.fr
02 32 88 81 42
Time Frame
Start Date: 2021-06-11
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 204
Treatments
Experimental: Primary anastomosis without protective stoma
Primary anastomosis without protective stoma
Active_comparator: Anastomosis with protective stoma
Anastomosis with protective stoma
Sponsors
Leads: University Hospital, Rouen

This content was sourced from clinicaltrials.gov